Analysts Offer Insights on Healthcare Companies: Corium (NASDAQ: CORI) and Aduro BioTech (NASDAQ: ADRO)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corium (NASDAQ: CORI) and Aduro BioTech (NASDAQ: ADRO) with bullish sentiments.

Corium (NASDAQ: CORI)

FBR Capital analyst Edward White reiterated a Buy rating on Corium (NASDAQ: CORI) today and set a price target of $18. The company’s shares opened today at $4.71.

White noted:

“Corium reported below-consensus revenue and EPS after the market close on November 21. While EPS and revenues were disappointing in the quarter, we believe that investors should continue to focus on the company’s impressive CNS patch pipeline. Corium has received favorable written feedback from the FDA regarding its development of Corplex donepezil and Corplex memantine. The FDA has indicated that if Corium can demonstrate bioequivalence between its products and oral Aricept (donepezil) and oral Namenda XR (memantine) in bioequivalence (BE) studies, then it could submit a 505(b)(2) NDA without conducting additional clinical efficacy trials. We believe meaningful catalysts are ahead in 2017. Patient dosing started in September for a pilot study for Corplex donepezil in preparation for the pivotal BE trial in 2H17.”

According to TipRanks.com, White is a 1-star analyst with an average return of -1.8% and a 37.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, RXi Pharmaceuticals Corp, and Synthetic Biologics Inc.

Corium has an analyst consensus of Moderate Buy.

Aduro BioTech (NASDAQ: ADRO)

In a report released yesterday, Christopher James from FBR Capital reiterated a Buy rating on Aduro BioTech (NASDAQ: ADRO). The company’s shares opened today at $14.10.

According to TipRanks.com, James is ranked 0 out of 5 stars with an average return of -7.0% and a 35.5% success rate. James covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Aviragen Therapeutics, Inc., and Achillion Pharmaceuticals.

Aduro BioTech has an analyst consensus of Strong Buy.